Clinical trials

Only want trials near your city that fit you? Get alerts

Disease

Country

Status

Phase

Reset

595 trials

NCT07138209
Recruiting
A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma
Phase 3 · China · 1 site
Registry update: 22 May 2026
NCT07226609
Recruiting
A Dietary Study for People With Multiple Myeloma
Not applicable · United States · 7 sites
Registry update: 5 May 2026
NCT07359014
Recruiting
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
Not applicable · China · 1 site
Registry update: 22 Jan 2026
NCT07497165
Recruiting
Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma
Not applicable · China · 1 site
Registry update: 27 Mar 2026
NCT07413809
Recruiting
Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen
Phase 3 · China · 1 site
Registry update: 17 Feb 2026
NCT07069751
Recruiting
A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma
Not applicable · Italy · 5 sites
Registry update: 3 Apr 2026
NCT07891923
Recruiting
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
Phase 2 · India · 2 sites
Registry update: 27 Oct 2026
NCT07369895
Recruiting
Clinical Study of O&D-001 Injection in the Treatment of Relapsed or Refractory Multiple Myeloma
Phase 1 · China · 1 site
Registry update: 27 Jan 2026
NCT07188090
Recruiting
Mozobil for Autologous Hematopoietic Stem Cell Transplantation
Phase 2 · United States · 1 site
Registry update: 28 Nov 2025
NCT07582354
Recruiting
MMAPPIN' Study: Multiple Myeloma Analysis For Patient-specific Insights to Dissect Disease Heterogeneity
Not applicable · Italy · 1 site
Registry update: 12 May 2026
NCT06517017
Recruiting
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Phase 2 · United States · 2 sites
Registry update: 23 Oct 2026
NCT06559033
Recruiting
Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS
Not applicable · France · 2 sites
Registry update: 10 Jun 2026
NCT06988488
Recruiting
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 1/2 · Canada, China, Germany, Spain, United Kingdom, Greece, Norway, United States · 22 sites
Registry update: 2 Sept 2026
NCT07149857
Recruiting
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
Phase 2 · Australia, Spain, United States · 20 sites
Registry update: 3 Nov 2026
NCT07116616
Recruiting
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 · United States · 10 sites
Registry update: 23 Sept 2026
NCT07489534
Recruiting
Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction
Phase 2 · China · 1 site
Registry update: 24 Mar 2026
NCT07101445
Recruiting
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
Phase 4 · United States · 1 site
Registry update: 23 Jul 2026
NCT06940297
Recruiting
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Phase 2 · United States · 1 site
Registry update: 26 Aug 2026
NCT06997081
Recruiting
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma (ADVANCE 2.0)
Phase 2 · United States · 1 site
Registry update: 21 Sept 2026
NCT07100067
Recruiting
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Not applicable · China · 3 sites
Registry update: 29 Dec 2025

Ordered by registry start date. Freshness and sponsorship never change the order.